GlaxoSmithKline (GSK) and South Korean pharmaceutical firm SK Bioscience have launched their Phase 3 trial. Covid-19 vaccine Collection, reported by the Press Association.
The GSK said Tuesday that the “positive” follow-up results in the Phase 1 and 2 study follow.
They are now aiming to deliver globally through the CoAX facility in the first half of 2022. It is subject to statistical and regulatory review.
The latest figures show that around 88 per cent of the UK population has been vaccinated at least one dose by people over the age of 16.
Thomas Brewer, Chief Global. Health A GSK official said, “Although many countries have made good progress with vaccinations, there is still a need for accessible and affordable Covid 19 vaccines to ensure equal access and to protect people around the world. ۔
“We are pleased to be partnering with GSK Epidemiology and working with SK to deliver vaccines on a large scale through Quakes.
The trial will be the basis for a vaccine against the Oxford / AstraZeneca vaccine to assess its safety and immunity.
The GSK said the study would be one of the first in a series of experiments globally to compare two different vaccine candidates.
Jiang Ahan, Chief Executive of SK Bioscience, said: “We are grateful that we have continued our Phase 3 study with unprecedented support for global initiatives, including the GSK, the Coalition for Epidemiological Pre-Initiative, and the Bill & Melinda Gates Foundation. Succeeded in growing.
“Taking this important step towards overcoming the global epidemic situation, SK and GSK will bring together our technical expertise to develop a protein-based vaccine candidate, GBP510.”